ArticleJournal of traditional and complementary medicine2025
Unveiling pharmacological targets of Rihimaside C for radiation-induced lung injury: An in silico and experimental integrated approach.
Article in Journal of traditional and complementary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pathological Mechanisms of Radiation-Induced Lung Injury and Novel Nano-Drug Delivery Therapeutic Strategies.International journal of nanomedicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aim: Radiation-induced lung injury (RILI) is a common complication during caner radiotherapy, mainly characterized by oxidative stress and inflammation. Rihimaside C, a novel dihydroflavonol compound isolated from Experimental procedure: Animal experiments were performed to evaluate the pharmacological efficacy of Rihimaside C for RILI. A computer-based strategy was employed to retrieve and screen potential targets for the therapy of Rihimaside C against RILI. STRING, DAVID databases, and Cytoscape software were utilized to construct a protein-protein interaction network and identify hub targets. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses were conducted to illuminate the underlying mechanisms. Molecular docking and Cellular Thermal Shift Assay (CETSA) were performed to further validate the hub targets. Results and conclusion: The results of animal experiments showed that Rihimaside C effectively alleviated RILI. Four hub targets (TNF, HSP90AA1, ESR1 and HIF1A) among the 72 possible targets of Rihimaside C involved in the treatment of RILI were finally identified through network pharmacology, which were enriched in MAPK, IL-17, and PI3K/Akt signaling pathways. Molecular docking and CETSA analyses indicated that HSP90AA1 displayed highest binding affinity with Rihimaside C. This study investigated the therapeutic effects of Rihimaside C on RILI and identified potential targets, providing a novel strategy in treating RILI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.